• Filter By:
• Specialty
• Source
• Condition
• Cancer
• Infectious Disease
• Drug
• Training
• Management
• Procedure
• Therapy
• Vaccine
• Nutrition
• Country

Transcatheter closure of patent foramen ovale to prevent stroke recurrence in patients with otherwise unexplained ischaemic stroke: Expert consensus of the French Neurovascular Society and the French Society of Cardiology.
CONCLUSIONS: Although a big step forward that will benefit many patients has been taken with recent trials, many questions remain unanswered. Pending results from further studies, decision-making regarding management of patients with PFO-associated ischaemic stroke should be based on a close coordination between neurologists/stroke specialists and cardiologists. PMID: 31378692 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - July 31, 2019 Category: Cardiology Authors: Mas JL, Derex L, Guérin P, Guillon B, Habib G, Juliard JM, Marijon E, Massardier E, Meneveau N, Vuillier F Tags: Arch Cardiovasc Dis Source Type: research

Safety of prasugrel in real-world patients with ST-segment elevation myocardial infarction: 1-year results from a prospective observational study (Bleeding and Myocardial Infarction Study).
CONCLUSION: The rate of major bleeding, particularly out-of-hospital bleeding, in patients treated with prasugrel is low within 1 year after a STEMI. Accurate selection of patient candidates for prasugrel is likely to have reduced the risk of bleeding. PMID: 26514325 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - October 26, 2015 Category: Cardiology Authors: Bacquelin R, Oger E, Filippi E, Hacot JP, Auffret V, Le Guellec M, Coudert I, Castellant P, Moquet B, Druelles P, Rialan A, Rouault G, Boulanger B, Treuil J, Leurent G, Bedossa M, Boulmier D, Avez B, Gilard M, Le Breton H Tags: Arch Cardiovasc Dis Source Type: research

Cytochrome CYP2C19 polymorphism and risk of adverse clinical events in clopidogrel-treated patients: A meta-analysis based on 23,035 subjects.
CONCLUSION: CYP2C19 polymorphism is significantly associated with risk of adverse clinical events in clopidogrel-treated patients. PMID: 24080325 [PubMed - as supplied by publisher]
Source: Archives of Cardiovascular Diseases - September 27, 2013 Category: Cardiology Authors: Mao L, Jian C, Changzhi L, Dan H, Suihua H, Wenyi T, Wei W Tags: Arch Cardiovasc Dis Source Type: research